Engineering safe anti-CD19-CD28ζ CAR T cells with CD8a hinge domain in serum-free media for adoptive immunotherapy
We have generated, validated, and characterized a reproducible indigenous workflow for generating anti-CD19 CAR T cells <i>in vitro.</i> This approach can be used for targeting cancer and autoimmune diseases in which CD19+ B lineage cells cause host damage.
Authors
- Muthuganesh Muthuvel
- Sunil S. Raikar (ORCID: https://orcid.org/0000-0003-2903-9542)
- Thamizhselvi Ganapathy
- Sunil Martin (ORCID: https://orcid.org/0000-0003-2712-6108)
- Saravanabhavan Thangavel (ORCID: https://orcid.org/0000-0001-6760-4106)
- Alok Srivastava (ORCID: https://orcid.org/0000-0002-2132-8123)
- H. Trent Spencer (ORCID: https://orcid.org/0000-0001-8062-2202)
Institutions
- Manipal Academy of Higher Education (IN)
- Christian Medical College, Vellore (IN)
- Rajiv Gandhi Centre for Biotechnology (IN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-05-09
- DOI
- https://doi.org/10.3389/fimmu.2025.1545549
- Citations
- 1
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 1.05